{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-003727","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.297625+00:00","generated_at":"2026-06-28T10:57:42.704705+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Janux reports Q3 net loss of $10.8M, cash $387.5M; IND filings on track for 2022","bullets":["Cash and equivalents $387.5M at Sept 30, 2021, up from $7.8M at Dec 31, 2020.","R&D expenses $8.4M (vs $0.8M in Q3 2020); G&A $3.6M (vs $0.4M).","PSMA-TRACTr IND submission expected H1 2022; EGFR-TRACTr IND expected H2 2022.","TRACIr costimulatory bispecific candidate selection planned in 2022.","Board strengthened with appointments of Ron Barrett (Ph.D.) and Alana McNulty."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-003727","json":"https://secwatch.observer/filing/0000950170-21-003727.json","markdown":"https://secwatch.observer/filing/0000950170-21-003727.md","text":"https://secwatch.observer/filing/0000950170-21-003727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017021003727/0000950170-21-003727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017021003727/janx-20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:57:42.704705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}